Product Description
Mechanisms of Action: CAR-T
Novel Mechanism: No
Modality: Cell Therapy
Route of Administration: Injection
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: BriStar
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
![Map of Global Clinical Trials for YTS-109](https://pryzm-maps.s3.us-west-2.amazonaws.com/666666current_maps.png)
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 0: Autoimmune Disease Unspecified
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
YTS109-003 | N/A |
Recruiting |
Systemic Vasculitis|Myositis|Lupus Erythematosus, Systemic|Antiphospholipid Syndrome|ANCA Vasculitis|Scleroderma, General|Lupus Vasculitis|Scleroderma, Systemic|Sjogren's Syndrome |
2025-04-21 |